曲妥珠单抗联合常规化疗治疗HER-2过度表达晚期贲门癌患者的临床效果与2年预后  

Clinical Effect and Two-year's Prognosis of Herceptin Combined with Conventional Chemotherapy in Treatment of Advanced Cardiac Carcinoma Patients with HER-2 Over Expression

作　　者：朱丽波[1] 马锐[1] 柳星[1] 沈晓宇[1] 李琳琳[1] 

机构地区：[1]辽宁省肿瘤医院,辽宁沈阳110042

出　　处：《现代生物医学进展》2013年第1期67-70,共4页Progress in Modern Biomedicine

摘　　要：目的:观察并探讨曲妥珠单抗(herceptin,HCP)联合常规化疗治疗HER-2过度表达晚期贲门癌患者的临床疗效与药物安全性分析并化疗后2年内随访结果。方法:将我院2008年11月-2009年10月间入选的HER-2表达"++"及以上的72例晚期贲门癌患者随机单盲分为观察组(37例)与对照组(35例),对照组患者采用DCF(多西紫杉醇、顺铂、5-氟尿嘧啶)动脉灌注化疗方案,观察组在此基础上联合使用靶向药物HCP,对比两组化疗结束后临床效果、生活质量改善情况、化疗中药物不良反应及2年内生存率。结果:①观察组与对照组化疗效果与生活质量改善情况构成不同(P<0.05),观察组部分缓解比例(62.2%)、总有效率(64.9%)及生活质量改善比例(64.9%)均高于对照组水平(42.9%、42.9%、42.9%);②两组不良发生情况相仿,观察组出现Ⅱ度及以发热(52.8%)、寒战(45.9%)比例与出现心功能障碍的比例(10.8%)高于对照组比例(22.9%、17.1%、0.0%);③观察组与对照组24个月生存率分别为43.2%、20.0%,死亡者平均存活时间分别为(14.7±2.8)m、(12.5±2.1)m,两指标差别均具有统计学意义(P<0.05)。结论:HCP联合DCF化疗方案能明显改善HER-2过度表达晚期贲门癌患者疗效与生活质量,并延长患者生存时间,但应警惕联合用药中的心血管毒性。Objective： The paper was to conduct an observation and discussion on clinical effect and 2 years＇ prognosis of her- ceptin（HCP） combined with conventional chemotherapy in treatment of advanced cardiac carcinoma patients with HER-2 over expression. Methods： 72 admitted cases with HER-2 expressing more than＂＋＋＂ ranging fi＇om Nov.2008 to Oct. 2009 were randomized into observa- tional group （37 cases） and control group （35 cases） single blindly, and conventional DCF （Docetaxel＋ cisplatin＋5-fluorouracil） chemotherapy scheme was applied to control group, based on which, targeting drug HCP combined with DCF scheme was exerted to ob- servational group. Comparison after the completion of chemotherapy was conducted between 2 groups on indicators of curative effect, life quality, adverse drug reactions （ADR）and 2 years survival rate. Results： （~Composition of curative effect and life quality of 2 groups was different （P〈0.05）, partial remission rate, total efficiency and improvement of quality of life scale of observation group were 62.2%, 64.9%, 64.9% respectively, while control group were 42.9%, 42.9%, 42.9% correspondingly; （1）Similar ADRs were seen between 2 groups, but proportions of patients with fever （52.8%）, chills （45.9%）classified into II degree and above, and with cardiac dysfunction （10.8%） were higher than those of control group （ 22.9%, 17.1%, 0%）;（~）24 months survival rates of 2 groups were 43.2%, 20.0%, mean survival time of deaths were （14.7± 2.8） m, （12.5 ± 2.1） m, both of which were statistically significant （P〈 0.05）. Conclusion： HCP plus DCF chemotherapy scheme can improve curative effect and life quality, prolong survival time of advanced cardiac cancer patients with HER-2 advanced expression, but attention should be paid to cardiovascular toxicity.

关 键 词：曲妥珠单抗 HER-2过度表达 贲门癌 疗效 生存率 

分 类 号：R735[医药卫生—肿瘤]